Skip to main content
. 2021 Jan 8;4(1):e2031661. doi: 10.1001/jamanetworkopen.2020.31661

Table 1. Comparisons of Baseline Characteristics of Patients With Rectal Cancer by Treatment Modality.

Characteristic No. (%) P value
Radiotherapy (n = 5310) No radiotherapy (n = 14 832)
Age at rectal cancer diagnosis, median (IQR), y 61 (52-70) 66 (56-75) <.001a
Age at rectal cancer diagnosis, y
20-49 1047 (19.7) 1767 (12) <.001b
50-69 2886 (54.4) 7230 (48.7)
≥70 1377 (25.9) 5835 (39.3)
Year of rectal cancer diagnosis, median (IQR) 1999 (1991-2006) 1993 (1984-2002) <.001a
Year of rectal cancer diagnosis
1975-1984 503 (9.5) 4095 (27.6) <.001b
1985-1994 1228 (23.1) 4063 (27.4)
1995-2004 1984 (37.4) 3983 (26.9)
≥2005 1595 (30) 2691 (18.1)
Race
White 4449 (83.8) 12 353 (83.3) <.001b
Black 352 (6.6) 1170 (7.9)
Otherc 509 (9.6) 1309 (8.8)
Tumor grade
Grade I/II 3992 (75.2) 9899 (66.7) <.001b
Grade III/IV 777 (14.6) 1141 (7.7)
Unknown 541 (10.2) 3792 (25.6)
Tumor stage <.001b
Localized 1742 (32.8) 11 393 (76.8)
Regional 3568 (67.2) 3439 (23.2)
Tumor histology
Adenocarcinoma 4831 (91) 14 181 (95.6) <.001b
Mucous tumor 360 (6.8) 490 (3.3)
Other 119 (2.2) 161 (1.1)
Tumor size, cm
<2 191 (3.6) 827 (5.6) <.001b
≥2 1306 (24.6) 1323 (8.9)
Unknown 3813 (71.8) 12 682 (85.5)
Chemotherapy
No 1293 (24.4) 13 892 (93.7) <.001b
Yes 4017 (75.6) 940 (6.3)
Follow-up time of patients with rectal cancer, mo, median (IQR) 120.5 (93-175) 154 (99-232) <.001a
Total person-years at risk 65 397 205 487
Latency between rectal cancer and SGMN, mo, median (IQR) 110 (69.3-156.5) 123.5 (63.3-137.8) <.001a
Patients who developed SGMN 144 (2.7) 176 (1.2) <.001b

Abbreviations: IQR, interquartile range; SGMN, second gynecological malignant neoplasm.

a

P values were calculated using the Mann-Whitney test for continuous variables and χ2 test.

b

P values were calculated using the Mann-Whitney test for categorical variables.

c

Other includes American Indian/Alaska Native and Asian/Pacific Islander.